萬城控股(02892.HK)作為反擔保人與龍光訂立反擔保合同
格隆匯 5 月 10日丨萬城控股(02892.HK)公佈,於2021年3月17日,合營公司(作為借款人)與貸款行訂立貸款合同,據此,貸款行同意按該合同所載條款及條件向合營公司授出本金人民幣4.20億元的貸款,用於在惠州發展物業開發項目。
合營公司由龍光(獨立第三方)的全資附屬公司及集團分別持有70%及30%股權。龍光須就合營公司在貸款合同項下之義務提供100%擔保。於2021年5月10日,公司(作為反擔保人)與龍光(獨立第三方,作為合營公司的擔保人)訂立反擔保合同,據此,公司同意根據該合同所載條款及條件(i)按集團所持合營公司的股權比例向龍光提供反擔保;及(ii)向龍光支付超額擔保費。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.